Eculizumab is a monoclonal antibody that binds with high affinity to the complement protein
C5, preventing terminal complement-mediated intravascular haemolysis in patients with …

Eculizumab has been developed as a breakthrough treatment for paroxysmal nocturnal
hemoglobinuria (PNH). Not only for breakthroughs, eculizumab therapy is also known to …

INTRODUCTION Paroxysmal nocturnal hemoglobinuria (PNH) patients treated with
eculizumab have an increased susceptibility to serious meningococcal infections. In the …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by
hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement …

Paroxysmal nocturnal hemoglobinuria (PNH) is a very rare acquired disease which is
characterized by increased sensitivity to complement proteins. The only curative treatment …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal, complement-mediated
hemolytic anemia with protean manifestations. PNH can present as a hemolytic anemia, a …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive, and life‐threatening
hematopoietic stem cell disorder characterized by complement‐mediated intravascular …

Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder
characterized by uncontrolled terminal complement activation. Eculizumab, a monoclonal …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic cell
disease characterized by the destruction of hematopoietic cells through activation of the …

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized
by complement-mediated intravascular hemolysis that is effectively treated with eculizumab …